Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
Ontology highlight
ABSTRACT: RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients who have undergone autologous stem cell transplant for high-risk lymphoma or multiple myeloma.
DISEASE(S): Multiple Myeloma And Plasma Cell Neoplasm,Small Intestine Cancer,Angioimmunoblastic T-cell Lymphoma,Plasmacytoma,Lymphoma,Intestinal Neoplasms,Neoplasms, Plasma Cell,Multiple Myeloma
PROVIDER: 2047201 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA